Gabapentin PD 400mg

Hauptinformation

  • Handelsname:
  • Gabapentin PD 400mg Kapsel
  • Darreichungsform:
  • Kapsel
  • Zusammensetzung:
  • Gabapentin 400.mg
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • für die Allgemeinheit:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie das Informationsblatt für die Öffentlichkeit.

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Gabapentin PD 400mg Kapsel
    Deutschland
  • Sprache:
  • Deutsch

Weitere Informationen

Status

  • Quelle:
  • BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte
  • Zulassungsnummer:
  • 31690.02.00
  • Letzte Änderung:
  • 01-12-2018

14-1-2019

Meer orgaan- en weefseltransplantaties in 2018

Meer orgaan- en weefseltransplantaties in 2018

In 2018 zijn in Nederland 815 orgaantransplantaties geweest en ruim 4000 patiënten geholpen met gedoneerd weefsel. Dit is een stijging van respectievelijk 15 en 18% in vergelijking met het jaar ervoor. Deze positieve jaarcijfers zijn gepubliceerd door de Nederlandse Transplantatie Stichting (NTS).

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

12-1-2019

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Assessment of the application for renewal of authorisation of selenomethionine produced by Saccharomyces cerevisiae NCYC R397 for all animal species

Published on: Fri, 11 Jan 2019 The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the application for renewal of authorisation of organic form of selenium produced by Saccharomyces cerevisiae NCYC R397 (Alkosel®) for all animal species. The FEEDAP Panel has delivered two opinions (on 2007 and 2016) on the safety and efficacy of the additive. The additive is characterised as organic selenium mainly selenomethionine (63%); it was ini...

Europe - EFSA - European Food Safety Authority EFSA Journal

1-12-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Trichoderma reesei (strain DP‐Nzd22)

Published on: Fri, 30 Nov 2018 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with a genetically modified Trichoderma reesei (strain DP‐Nzd22) by DuPont. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The endo‐1,4‐β‐xylanase is intended to be used in distilled alcohol production, bakery and brewery. Residual amounts of total organic solids (TOS) are removed during the production of dis...

Europe - EFSA - European Food Safety Authority Publications

30-11-2018

Data collection for the estimation of ecological data (specific focal species, time spent in treated areas collecting food, composition of diet), residue level and residue decline on food items to be used in the risk assessment for birds and mammals

Data collection for the estimation of ecological data (specific focal species, time spent in treated areas collecting food, composition of diet), residue level and residue decline on food items to be used in the risk assessment for birds and mammals

Published on: Thu, 29 Nov 2018 The study described in this report was conducted with the aim of developing an unified database of ecological data and residue data to be used for the risk assessment of plant protection products for birds and mammals. The main sources of data were the information submitted in the context of approval of active substances and authorization of products and and additional information retrieved through a systematic literature review. The data were screened and organised in thr...

Europe - EFSA - European Food Safety Authority Publications

20-11-2018

Überprüfung

Überprüfung

Gabapentin zur Behandlung der Spastik im Rahmen der Multiplen Sklerose

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

1-11-2018

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in starch processing for glucose syrups production, beverage alcohol (distilling) processes and baking proces...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Published on: Fri, 19 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to evaluate the genotoxic potential of 74 flavouring substances from subgroup 1.1.1 of FGE.19 in the Flavouring Group Evaluation 200 Revision 1 (FGE.200 Rev1). In FGE.200, genotoxicity studies were provided for one representative substance, namely hex‐2(trans)‐enal [FL‐no: 05.073], and for other two substances in the same subgroup, namely 2‐dodecenal [FL‐no: 05.03...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

2-10-2018

Forthyron 400 ad us. vet., Tabletten

Forthyron 400 ad us. vet., Tabletten

● Die Zulassung ist am 02.10.2018 erloschen.

Institut für Veterinärpharmakologie und toxikologie

18-9-2018

Einführung in die Thematik, gesetzliche Rahmenbedingungen, Definitionen und Abgrenzungsfragen bei Studien mit Arzneimitteln

Einführung in die Thematik, gesetzliche Rahmenbedingungen, Definitionen und Abgrenzungsfragen bei Studien mit Arzneimitteln

Vortragsfolien von Dr. Claudia Riedel und PD Dr. Thomas Sudhop, BfArM, im Rahmen der Veranstaltung "BfArM im Dialog - Abgrenzung von Klinischen Prüfungen" vom 04. September 2018

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

18-9-2018

Rolle der Landesbehörden bei der Abgrenzung: Zuständigkeiten und Entscheidungsprozesse

Rolle der Landesbehörden bei der Abgrenzung: Zuständigkeiten und Entscheidungsprozesse

Vortragsfolien von PD Dr. Thomas Sudhop, BfArM, im Rahmen der Veranstaltung "BfArM im Dialog - Abgrenzung von Klinischen Prüfungen" vom 04. September 2018

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

18-9-2018

Ausblick auf die Verordnung (EU) Nr. 536/2014 zu Klinischen Prüfungen mit Arzneimitteln

Ausblick auf die Verordnung (EU) Nr. 536/2014 zu Klinischen Prüfungen mit Arzneimitteln

Vortragsfolien von PD Dr. Thomas Sudhop, BfArM, im Rahmen der Veranstaltung "BfArM im Dialog - Abgrenzung von Klinischen Prüfungen" vom 04. September 2018

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

31-8-2018

Public Notification: PremierZen Gold 4000 contains hidden drug ingredient

Public Notification: PremierZen Gold 4000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use PremierZen Gold 4000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

22-8-2018

Pexion 400 mg ad us. vet., Tabletten

Pexion 400 mg ad us. vet., Tabletten

● Änderung Text "Unerwünschte Wirkungen" und "Wechselwirkungen"

Institut für Veterinärpharmakologie und toxikologie

3-8-2018

Scientific guideline:  Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

27-7-2018

Dringende Sicherheitsinformation zu ARCHITECT c4000 / c8000 / c16000 Processing Module von Abbott Laboratories (Abbott Park)

Dringende Sicherheitsinformation zu ARCHITECT c4000 / c8000 / c16000 Processing Module von Abbott Laboratories (Abbott Park)

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

14-6-2018

Blokhuis: maak postnatale depressie bespreekbaar

Blokhuis: maak postnatale depressie bespreekbaar

In Nederland ontwikkelen jaarlijks ruim 23.400 vrouwen een depressie na de bevalling. Dat is 1 op de 8 moeders. Velen van hen durven hun situatie niet aan te kaarten. Zij zijn bang om gezien te worden als een slechte moeder (47,4%) en willen anderen niet belasten (52,2%), blijkt uit een peiling onder vrouwen die (signalen van) een postnatale depressie hebben gehad. Hierdoor blijft postnatale depressie, ook wel postpartum depressie (PPD) genoemd, te vaak onbesproken. Daarom geeft staatssecretaris Paul Blo...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

11-1-2019

Cerezyme® 400 Units

Rote - Liste

10-1-2019

MisoOne 400 Mikrogramm Tabletten

Rote - Liste

19-12-2018

Ciprobay® 400 mg

Rote - Liste

11-12-2018

Quetiapin TAD® 400 mg Retardtabletten

Rote - Liste

6-12-2018

Imanivec® 400 mg Filmtabletten

Rote - Liste

5-12-2018

Uniphyllin® 300 mg/400 mg/600 mg

Rote - Liste

1-12-2018

SYLVANT® 100 mg / 400 mg

Rote - Liste

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): gabapentin, decision type: , therapeutic area: , PIP number: P/0198/2018

Opinion/decision on a Paediatric investigation plan (PIP): gabapentin, decision type: , therapeutic area: , PIP number: P/0198/2018

Opinion/decision on a Paediatric investigation plan (PIP): gabapentin, decision type: , therapeutic area: , PIP number: P/0198/2018

Europe - EMA - European Medicines Agency

22-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type:

Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type:

Opinion/decision on a Paediatric investigation plan (PIP): Citric acid (as citric acid anhydrous) / sodium chloride / simeticone / macrogol 4000 / sodium citrate /sodium sulfate (as sodium sulfate anhydrous) / potassium chloride (PMF104), decision type: , therapeutic area: , PIP number: P/0223/2018

Europe - EMA - European Medicines Agency

25-10-2018

Sovaldi® 400mg Filmtabletten

Rote - Liste

11-10-2018

Avalox® 400 mg/250 ml Infusionslösung

Rote - Liste

8-10-2018

ISENTRESS 400 mg Filmtabletten

Rote - Liste

14-9-2018

Gabapentin AbZ 600 mg Filmtabletten

Rote - Liste

14-9-2018

Gabapentin AbZ 800 mg Filmtabletten

Rote - Liste

30-7-2018

Ibu Teva® 400 mg Filmtabletten

Rote - Liste

30-7-2018

Dolgit® 200/400

Rote - Liste

26-7-2018

Harvoni® 90 mg/400 mg Filmtabletten

Rote - Liste

25-7-2018

#FDA issues updated safety communication for Zoll LifeVest 4000 regarding “Message Code 102,” and updated patient checklist.  https://go.usa.gov/xUEPn  #MedicalDevices

#FDA issues updated safety communication for Zoll LifeVest 4000 regarding “Message Code 102,” and updated patient checklist. https://go.usa.gov/xUEPn  #MedicalDevices

#FDA issues updated safety communication for Zoll LifeVest 4000 regarding “Message Code 102,” and updated patient checklist. https://go.usa.gov/xUEPn  #MedicalDevices

FDA - U.S. Food and Drug Administration

19-7-2018

Regulatory and procedural guideline:  Qualification opinion on dopamine transporter imaging as an enrichment biomarker for Parkinson’s disease clinical trials in patients with early Parkinsonian symptoms, adopted

Regulatory and procedural guideline: Qualification opinion on dopamine transporter imaging as an enrichment biomarker for Parkinson’s disease clinical trials in patients with early Parkinsonian symptoms, adopted

Critical Path Global Ltd.’s Critical Path for Parkinson’s (CPP) is a multinational consortium of the Critical Path Institute supported by Parkinson’s UK and industry. This broad collaboration of pharmaceutical companies, government agencies, academic institutions, and charities aims to accelerate the development of therapies for Parkinson’s disease (PD).

Europe - EMA - European Medicines Agency

16-7-2018

Avalox® 400 mg Filmtabletten

Rote - Liste

5-7-2018

Sanasthmax® 400 Mikrogramm

Rote - Liste

14-6-2018

Gabapentin AbZ 100 mg Hartkapseln

Rote - Liste